HUP0104126A2 - Gyógyszer a csontmetabolizmus hibáira - Google Patents

Gyógyszer a csontmetabolizmus hibáira

Info

Publication number
HUP0104126A2
HUP0104126A2 HU0104126A HUP0104126A HUP0104126A2 HU P0104126 A2 HUP0104126 A2 HU P0104126A2 HU 0104126 A HU0104126 A HU 0104126A HU P0104126 A HUP0104126 A HU P0104126A HU P0104126 A2 HUP0104126 A2 HU P0104126A2
Authority
HU
Hungary
Prior art keywords
bone
pathobolism
remedies
agent
derivatives
Prior art date
Application number
HU0104126A
Other languages
English (en)
Inventor
Nobuaki Fujise
Kanji Higashio
Chiharu Masuyama
Shinichi Mochizuki
Eisuke Tsuda
Original Assignee
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company, Limited filed Critical Sankyo Company, Limited
Publication of HUP0104126A2 publication Critical patent/HUP0104126A2/hu
Publication of HUP0104126A3 publication Critical patent/HUP0104126A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

lign=F;>(57) A találmány tárgya csontpatobolizmust kezelő szer. Ez acsontpatobolizmust kezelő szer tartalmaz legalább egy anyagot azoszteoklasztogenezis-gátló faktor (OCIF) homológjai és variánsaiközül, továbbá egy poliszacharidot vagy származékait.Poliszacharidként vagy származékaiként heparin, dextrán-szulfát éshasonlók alkalmazhatók. A találmány szerinti csontpatobolizmus-kezelőszernek kiváló gyógyászati hatása van a csontpatobolizmus ellen,amilyen például a csontritkulás, hiperkalcémia vagy krónikus ízületireuma, és kiváló hatása van az aktivitás tartósságára. A szerhasznosan alkalmazható gyógyszerként. Ó
HU0104126A 1998-10-28 1999-10-28 Remedies for bone metabolic errors HUP0104126A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32287498 1998-10-28
PCT/JP1999/005963 WO2000024416A1 (fr) 1998-10-28 1999-10-28 Agents therapeutiques pour deformations osseuses

Publications (2)

Publication Number Publication Date
HUP0104126A2 true HUP0104126A2 (hu) 2002-03-28
HUP0104126A3 HUP0104126A3 (en) 2004-07-28

Family

ID=18148585

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104126A HUP0104126A3 (en) 1998-10-28 1999-10-28 Remedies for bone metabolic errors

Country Status (21)

Country Link
US (1) US6919312B2 (hu)
EP (1) EP1127578A4 (hu)
JP (1) JP3860415B2 (hu)
KR (1) KR20010082272A (hu)
CN (1) CN1183961C (hu)
AU (1) AU755422B2 (hu)
BR (1) BR9914834A (hu)
CA (1) CA2347107A1 (hu)
CZ (1) CZ20011378A3 (hu)
HK (1) HK1042847A1 (hu)
HU (1) HUP0104126A3 (hu)
IL (1) IL142557A0 (hu)
MX (1) MXPA01004225A (hu)
NO (1) NO20012106L (hu)
NZ (1) NZ511506A (hu)
PL (1) PL347559A1 (hu)
RU (1) RU2223782C2 (hu)
TR (1) TR200101146T2 (hu)
TW (1) TW529954B (hu)
WO (1) WO2000024416A1 (hu)
ZA (1) ZA200103296B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
IL142557A0 (en) 1998-10-28 2002-03-10 Snow Brand Milk Products Co Ltd Remedies for bone metabolic errors
US6593310B1 (en) * 2000-11-21 2003-07-15 Arthropharm Pty. Ltd. Treatment of osteoporosis
MXPA03008895A (es) 2001-04-03 2005-03-07 Nestle Sa Osteoprotegerina de la leche y sus uso.
CZ20022231A3 (cs) * 2001-06-29 2003-02-12 Sankyo Company Limited Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu
WO2003074084A1 (en) * 2002-03-01 2003-09-12 Sankyo Company, Limited A pharmaceutical composition
WO2003103710A1 (ja) * 2002-06-07 2003-12-18 三共株式会社 骨破壊の治療または予防剤組成物の併用効果
CA2912012C (en) 2005-05-05 2018-05-29 Sensient Flavors Inc. Production of beta-glucans and mannans
TW200820980A (en) * 2006-10-02 2008-05-16 Nat Inst For Materials Science A sustained-release preparation having osteoconductive activity
WO2008077257A1 (en) * 2006-12-22 2008-07-03 Mathys Ag Bettlach Precursor for the preparation of a pasty bone replacement material by admixture of a liquid
AU2010328726B2 (en) * 2009-12-09 2017-01-19 Agency For Science, Technology And Research Glycosaminoglycan mixtures
CN111454899B (zh) * 2020-04-30 2021-04-20 青岛思拓新源细胞医学有限公司 角叉菜多糖在抑制间充质干细胞成脂转化中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2604135B2 (ja) * 1986-02-28 1997-04-30 ライオン株式会社 口腔骨疾患治療剤
IL91438A (en) * 1989-08-25 1995-03-30 Bukh Meditec Preparation for treating dental disease
TW318142B (hu) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
CA2257247C (en) 1997-04-15 2012-09-11 Snow Brand Milk Products Co., Ltd. Novel protein binding to osteoclastogenesis inhibitory factor and process for producing the same
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
CN1183159C (zh) 1997-09-24 2005-01-05 三共株式会社 破骨细胞形成抑制因子单克隆抗体、其用途和试剂盒
US6214838B1 (en) 1998-06-15 2001-04-10 Takeda Chemical Industries, Ltd. Thienodipyridine derivatives, production and use thereof
IL142557A0 (en) 1998-10-28 2002-03-10 Snow Brand Milk Products Co Ltd Remedies for bone metabolic errors
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
EP1140136B1 (en) * 1999-09-03 2007-05-16 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2001044472A1 (en) 1999-12-16 2001-06-21 Amgen, Inc. Tnfr/opg-like molecules and uses thereof
CZ20022231A3 (cs) * 2001-06-29 2003-02-12 Sankyo Company Limited Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu
WO2003074084A1 (en) * 2002-03-01 2003-09-12 Sankyo Company, Limited A pharmaceutical composition

Also Published As

Publication number Publication date
US20010031725A1 (en) 2001-10-18
PL347559A1 (en) 2002-04-08
BR9914834A (pt) 2001-08-14
JP3860415B2 (ja) 2006-12-20
IL142557A0 (en) 2002-03-10
MXPA01004225A (es) 2002-06-04
CA2347107A1 (en) 2000-05-04
EP1127578A4 (en) 2004-12-15
AU755422B2 (en) 2002-12-12
NZ511506A (en) 2004-02-27
NO20012106L (no) 2001-06-21
EP1127578A1 (en) 2001-08-29
US6919312B2 (en) 2005-07-19
NO20012106D0 (no) 2001-04-27
RU2223782C2 (ru) 2004-02-20
ZA200103296B (en) 2001-10-25
KR20010082272A (ko) 2001-08-29
CN1325310A (zh) 2001-12-05
AU6487799A (en) 2000-05-15
WO2000024416A1 (fr) 2000-05-04
CN1183961C (zh) 2005-01-12
TR200101146T2 (tr) 2001-09-21
TW529954B (en) 2003-05-01
HUP0104126A3 (en) 2004-07-28
CZ20011378A3 (cs) 2001-10-17
HK1042847A1 (zh) 2002-08-30

Similar Documents

Publication Publication Date Title
HUP0104126A2 (hu) Gyógyszer a csontmetabolizmus hibáira
BR9911072A (pt) Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépicos e/ou agentes promotores da cura de feridas no trato respiratório inferior
HUP0301452A2 (hu) Fotokemoterápiás szert és mukoadhéziós szert tartalmazó gyógyszerkészítmény és alkalmazása
HUP0301729A2 (hu) Gyógyszer szívelégtelenség megelżzésére és kezelésére
HUP0002755A2 (hu) Eljárások szklerózis multiplexben szenvedő betegek kezelésére konszenzus interferonnal
HUP0004170A2 (hu) Eljárás és anyagok nyálkaszövetek gyulladásának kezelésére és megelőzésére
ATE369126T1 (de) Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung
TR200401545T4 (tr) NOSS inhibitörü ilaçların amalatı için ikame imidazo [1,2-a]piridin-,-pirimidin- ve-pirazin-3-amin-türevlerinin kullanımı
HUP0200033A2 (hu) Jégtelenítő oldat
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
BR9809968A (pt) Aplicação de derivados tiazolidinadiona no tratamento da pcos e diabetes gestacional
BR0110838A (pt) Agente de emplastro
BR9808678A (pt) Composição de tratamento da superfìcie de dentes, processos de tratamento e de restauração adesiva de uma estrutura de dentes
BR0309256A (pt) Sistemas de liberação responsivos à temperatura
BRPI0408491A (pt) tratamento da doença de alzheimer
HUP0102456A2 (hu) Valproesav analógok alkalmazása migrén és affektív betegségek kezelésére és megelőzésére
US20040097936A1 (en) Set of osteosynthesis plates -5 variants of the same basic type
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
PT1214061E (pt) Nova utilizacao de docetaxel para o tratamento do carcinoma hepatocelular
SE0103575D0 (sv) System for fixation of fractures
BR9908716A (pt) Tratamento de disfunção sexual em certos grupos de pacientes
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica
BRPI0418017A (pt) medicamento compreendendo inibidores de pentraxina ptx3 longa
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses